HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia

NewTimeSpace News: Hansoh Pharmaceutical Group Company Limited (stock code: 03692) announced that the board of directors is pleased to announce that HS-10582 tablets, a Class 1 new drug independently developed by the Group, has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) of China, intended for clinical trials for the treatment of primary hypercholesterolemia and mixed dyslipidemia in adults.

The announcement disclosed that HS-10582 tablets is a Class 1 innovative drug independently developed by the Group. The approval of the clinical trial marks new progress in the research and development of the product in the cardiovascular and metabolic disease field, further enriching the Group's innovative drug pipeline.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.